Latest prostatectomy Stories

NEW YORK, June 23, 2011 /PRNewswire/ -- For years, researchers have dreamed of curing prostate cancer with targeted drugs that could modulate the body's own immune system to attack and destroy malignant cancer cells. Recent approvals of immuno-modulatory drugs Provenge and Yervoy represent considerable progress in this domain, as they have already been shown to improve survival rates in certain types of metastatic prostate cancer. Over 20 other such drugs are expected to seek approval in...

MOUNTAIN VIEW, Calif., June 17, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that the positive results from REVIVE-RP (TA-303), a phase 3 clinical trial evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED),will be presented this afternoon at the 2011 Cancer Survivorship and Sexual Health Symposium in Washington D.C. The meeting is jointly sponsored by the International Society for Sexual Medicine (ISSM)...

1 in 6 Men will be Diagnosed with Cancer of the Prostate during their Lifetime*. Westchester County, New York (PRWEB) June 15, 2011 Quality, patient centered care that's close to home"”That's Northern Westchester Hospital. There are many reasons men don't visit the doctor on a regular basis. For one, men don't view visiting their doctor as part of preventative care the way women do. Many women begin seeing a gynecologist during their teenage years and then continue doing so on an...

Receiving radiation therapy immediately after a radical prostatectomy is a cost-effective treatment for prostate cancer patients when compared with waiting and acting on elevated prostate-specific antigen (PSA) levels, according to a new study by researchers at Thomas Jefferson University and Hospital.What's more, a separate, but related study, found that urologists were less likely than radiation oncologists to recommend adjuvant radiation therapy or to believe it improves overall...

NEW YORK, June 8, 2011 /PRNewswire/ -- The rapid adoption of robotic prostatectomy in the US is leading more men to choose surgery as their primary treatment for prostate cancer, according to a study presented at the annual American Urological Association meeting and co-authored by Dr. David Samadi. Interestingly, this finding occurred amid a national decrease in prostate cancer incidence. "This means that more surgeons and hospitals are adopting robotic surgery technology and more...

NEW YORK, June 6, 2011 /PRNewswire/ -- According to research presented by Dr. David B. Samadi, a prostate cancer treatment, robotic prostatectomy, and prostate surgery expert, at the annual meeting of the American Urological Association men taking statins, a class of widely used cholesterol-lowering drugs, have significantly lower serum PSA (prostate-specific antigen) levels than their non statin-using counterparts. (Photo: http://photos.prnewswire.com/prnh/20110606/NY14928 ) This PSA...

NEW YORK, May 26, 2011 /PRNewswire/ -- A new prostate cancer study published in the New England Journal of Medicine comparing surgical treatment to "watchful waiting" revealed important findings for patients newly diagnosed with prostate cancer and currently debating their treatment options. (Photo: http://photos.prnewswire.com/prnh/20110526/NY09899 ) Two of the most commonly offered clinical options for early prostate cancer treatment today are "watchful waiting" and radical...

NEW YORK, May 17, 2011 /PRNewswire/ -- Dr. David B. Samadi, Vice Chairman, Department of Urology, and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York City appeared on Fox News to discuss a new study on prostate cancer treatment published by the New England Journal of Medicine. As a member of Fox News' Medical A-Team, Samadi was encouraged by the study results with regards to prostate cancer treatment. "The study shows a definite survival...

Long-term survival rates for patients with advanced prostate cancer suggest they can be good candidates for surgery, Mayo Clinic researchers have found. Their study found a 20-year survival rate for 80 percent of patients diagnosed with cancer that has potentially spread beyond the prostate, known as cT3 prostate cancer, and treated with radical prostatectomy, or surgery to remove the prostate gland. Previously, patients found to have cT3 prostate cancer were offered radiation or hormone...

NEW YORK, May 9, 2011 /PRNewswire/ -- Robotic prostatectomy and prostate cancer treatment expert Dr. David Samadi, Vice Chairman, Department of Urology, and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York City, says a return to a normal sex life can be achieved after robotic prostate surgery. Thanks to the nerve-sparing feature of his signature surgical technique, a majority of men (85%) recover their potency within one year of the procedure....